Unlocking Exciting Opportunities for Investors

We are thrilled to share that PharmBot AI has received Seed Enterprise Investment Scheme (SEIS) Advance Assurance from HMRC. This milestone paves the way for potential investors to join our mission of revolutionising pharmacy operations through cutting-edge AI technology while benefiting from one of the most attractive tax relief schemes available in the UK.

 

What is SEIS and Why Does It Matter?

The Seed Enterprise Investment Scheme (SEIS) is a government-backed initiative designed to encourage investment in early-stage companies by offering substantial tax incentives to investors. For startups like PharmBot AI, securing SEIS approval is a significant milestone that highlights our eligibility for this scheme.
For investors, SEIS offers generous tax benefits when they invest in innovative companies at an early stage, mitigating risk while maximising the potential for returns.

 

The Benefits of SEIS for Investors

Investing under SEIS comes with a range of advantages that make it highly attractive for individuals looking to support growing companies:

1. Income Tax Relief

Investors can claim up to 50% income tax relief on their investment, up to a maximum of £200,000 per tax year.
Example: A £10,000 investment could result in £5,000 back as income tax relief.

2. Capital Gains Tax (CGT) Exemption

Any profits made from SEIS shares are exempt from Capital Gains Tax if the shares are held for at least 3 years.

3. Loss Relief

If the company doesn’t succeed, investors can offset any losses against their tax bill, further reducing financial risk.

4. Inheritance Tax Relief

SEIS shares are exempt from Inheritance Tax if held for 2 years or more.

5. Reinvestment Relief

Investors can also benefit from reinvesting capital gains into SEIS-qualifying companies, reducing CGT on other investments.

 

Why SEIS Approval is a Milestone for PharmBot AI

PharmBot AI is on a mission to transform pharmacy operations through AI-driven solutions, starting with our flagship Prescription Verification Service. By securing SEIS approval, we are now in a stronger position to attract early-stage investors who are passionate about innovation in healthcare technology.

This approval signals:
  • Our commitment to building a scalable, forward-thinking solution.
  • Our eligibility under a scheme that prioritises innovation and economic growth.
  • Confidence that investors can benefit from tax relief while supporting a company solving real-world healthcare challenges.

 

Why Now is the Time to Invest in PharmBot AI

The healthcare industry is undergoing a massive digital transformation, and PharmBot AI is at the forefront of this change. From improving prescription accuracy to tackling medication adherence, we are building AI-powered tools that will streamline operations, enhance patient safety, and drive efficiency across pharmacy systems.
For early investors, SEIS not only makes investing in PharmBot AI financially attractive but also offers a unique opportunity to be part of a high-growth company at the start of its journey.

 

Join Us in Shaping the Future of Pharmacy

PharmBot AI is now SEIS-approved and open for investment. If you are an investor looking to back innovative healthcare technology while benefiting from substantial tax incentives, this is the perfect time to connect with us.

We are excited to partner with forward-thinking investors who share our vision of transforming pharmacy operations through technology and innovation.

 

Interested in learning more?

Feel free to reach out to us at info@pharmbotai.com or visit www.pharmbotai.com for more details.

Let’s build the future of pharmacy together.